Nephros Q2 2026 Earnings: Revenue Rises 36% as Tariff Refund Lifts Margins

Nephros (Nasdaq: NEPH) reported Q2 2026 net revenue of $6.017 million, up 36% from $4.419 million a year earlier, while diluted EPS increased to $0.11 from $0.02. Net income reached $1.197 million, although the quarter included an approximately $0.6 million one-time tariff refund; core programmatic revenue grew 27%, and service-related revenue nearly tripled.

Core financial results

Revenue grew substantially faster than operating expenses, helping operating income and adjusted EBITDA rise alongside the tariff-related gross-profit benefit. Total operating expenses increased about 10%, compared with the 36% increase in revenue.

The one-time refund materially affected year-over-year profit comparability. Nephros recognized most of the approximately $0.6 million refund as a reduction in cost of goods sold, but had not received the cash as of quarter-end.

Adjusted EBITDA is a non-GAAP measure that excludes interest, taxes, depreciation, amortization, stock-based compensation, and certain other non-cash items.

Business and revenue mix

Product revenue remained the largest contributor, rising about 32%. Service, royalty, and other revenue increased to $316,000 from $108,000, with management attributing the service growth to demand for installation, filter replacement, and water-management support.

Core programmatic revenue increased 27%. Management views this recurring replacement business as important because it supports repeat demand and longer-term customer relationships. Nephros also reported customer interest in newer products addressing microplastics, nanoplastics, PFAS, sterile processing, drinking fountains, and bottle fillers, but did not quantify their revenue contribution.

Tariff refund amplified the profit improvement

The approximately $0.6 million tariff refund was the most important factor affecting reported profitability. It followed the invalidation of tariffs previously paid under the International Emergency Economic Powers Act, and Nephros recorded most of the approved claim as lower cost of goods sold during the quarter.

The refund lifted gross margin, but several factors offset part of the benefit: a weaker U.S. dollar relative to the euro, higher shipping expenses, and rapid growth in service revenue, which carries lower margins than product sales. Nephros did not provide an adjusted gross margin excluding the refund, so the underlying margin cannot be stated precisely.

Operating leverage also contributed to the earnings increase. Selling, general, and administrative expenses rose 10% to $2.418 million because of higher headcount and sales commissions, while research and development expenses increased 18% to $366,000 due to higher salary costs. Both grew more slowly than revenue.

Liquidity and balance sheet

Nephros ended June 2026 with $4.697 million in cash and cash equivalents, down from $5.400 million at the end of 2025, while remaining debt-free. Accounts receivable increased to $4.096 million from $2.414 million, and inventory rose to $4.547 million from $3.232 million. Accounts payable also increased to $1.965 million from $914,000.

The higher receivables and inventory indicate that more capital was tied up in working-capital accounts as the business expanded. In addition, the tariff refund had been recognized in earnings but not yet collected in cash. Because the release did not include operating cash-flow data, the precise effect of each balance-sheet movement on cash generation cannot be determined.

Recent insider transactions

The supplied six-month insider summary records zero purchase transactions and zero sale transactions, with total insider holdings of approximately 1.4 million shares. Separately, the data lists two direct derivative-security exercises on March 23, 2026; these should not be treated as open-market purchases.

Risks investors should monitor

• Profit comparability: The approximately $0.6 million tariff refund was a one-time benefit, making reported gross margin, net income, and EPS less representative of recurring quarterly profitability.
• Cost and currency pressure: Dollar weakness against the euro and higher shipping expenses continued to raise product costs and could pressure margins without another offsetting benefit.
• Lower-margin revenue mix: Service revenue is growing much faster than total revenue but produces lower gross margins than product sales, creating a potential trade-off between growth and profitability.
• Working-capital demands: Receivables and inventory grew faster than revenue from year-end levels, while cash declined. Continued expansion could require additional working capital even if the company remains profitable.
• Refund collection timing: The approved tariff refund had not been received by June 30, leaving a temporary difference between recognized earnings and cash realization.

Summary

Nephros delivered record quarterly revenue as programmatic product demand and service activity expanded, while operating expenses grew more slowly than sales. The tariff refund significantly enhanced reported profitability, so the next key measures are whether recurring revenue growth continues, how gross margin performs without the one-time benefit, and whether higher receivables and inventory convert into cash efficiently.